Dashboard
Manage Tickers

ABBVAbbVie Inc.

NYSE abbvie.com


$ 189.35 $ -1.61 (-0.84 %)    

Friday, 09-Aug-2024 10:01:49 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 446.72 $ 0.95 (0.21 %)
DIA $ 393.43 $ -0.12 (-0.03 %)
SPY $ 529.63 $ 1.00 (0.19 %)
TLT $ 96.34 $ 0.19 (0.2 %)
GLD $ 224.37 $ -0.46 (-0.2 %)
$ 190.4
$ 190.96
$ 189.36 x 100
$ 193.65 x 200
$ 188.57 - $ 190.96
$ 132.11 - $ 193.91
5,743,458
na
337.2B
$ 0.63
$ 63.16
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-03-2024 03-31-2024 10-Q
3 02-20-2024 12-31-2023 10-K
4 11-06-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-05-2023 03-31-2023 10-Q
7 02-17-2023 12-31-2022 10-K
8 11-04-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-06-2022 03-31-2022 10-Q
11 02-18-2022 12-31-2021 10-K
12 11-02-2021 09-30-2021 10-Q
13 08-02-2021 06-30-2021 10-Q
14 05-07-2021 03-31-2021 10-Q
15 02-19-2021 12-31-2020 10-K
16 11-04-2020 09-30-2020 10-Q
17 08-04-2020 06-30-2020 10-Q
18 05-08-2020 03-31-2020 10-Q
19 02-21-2020 12-31-2019 10-K
20 11-06-2019 09-30-2019 10-Q
21 08-05-2019 06-30-2019 10-Q
22 05-03-2019 03-31-2019 10-Q
23 02-27-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-07-2018 06-30-2018 10-Q
26 05-04-2018 03-31-2018 10-Q
27 02-16-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-07-2017 06-30-2017 10-Q
30 05-05-2017 03-31-2017 10-Q
31 02-17-2017 12-31-2016 10-K
32 11-07-2016 09-30-2016 10-Q
33 08-05-2016 06-30-2016 10-Q
34 05-06-2016 03-31-2016 10-Q
35 02-19-2016 12-31-2015 10-K
36 11-06-2015 09-30-2015 10-Q
37 08-07-2015 06-30-2015 10-Q
38 05-08-2015 03-31-2015 10-Q
39 02-20-2015 12-31-2014 10-K
40 11-07-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

warren-buffetts-approach-to-investing-in-election-years
Warren Buffett's Approach To Investing In ...
08/07/2024 15:33:49

Warren Buffett, known as the 'Oracle of Omaha', is a highly successful American investor who manages his portfolio cons...

abbvie-leidos-kkr-and-more-on-cnbcs-final-trades
AbbVie, Leidos, KKR And More On CNBC's 'Fi...
08/06/2024 12:43:42

cantor-fitzgerald-reiterates-overweight-on-abbvie-maintains-200-price-target
Cantor Fitzgerald Reiterates Overweight on...
08/05/2024 18:05:52

Cantor Fitzgerald analyst Louise Chen reiterates AbbVie (NYSE:ABBV) with a Overweight and maintains $200 price target.

Core News & Articles
CNBC Halftime Report Final Trades: KKR & C...
08/05/2024 17:01:16

heres-how-much-you-would-have-made-owning-abbvie-stock-in-the-last-10-years
Here's How Much You Would Have Made Owning...
08/02/2024 21:00:19

8-health-care-stocks-with-whale-alerts-in-todays-session
8 Health Care Stocks With Whale Alerts In ...
08/01/2024 17:35:24

Core News & Articles
CNBC Halftime Report Final Trades: Amazon....
08/01/2024 17:00:36

a-closer-look-at-abbvies-options-market-dynamics
A Closer Look at AbbVie's Options Market D...
07/31/2024 15:16:03

bristol-myers-johnson--johnson-abbvie-astrazeneca-expect-minimal-impact-from-upcoming-medicare-price-negotiations
Bristol Myers, Johnson & Johnson, AbbVie, ...
07/30/2024 18:12:15

Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact fro...

abbvie-wins-analyst-confidence-with-q2-beat-diverse-portfolio-fuels-long-term-growth-expectations
AbbVie Wins Analyst Confidence with Q2 Bea...
07/26/2024 18:54:10

AbbVie reports Q2 earnings with adjusted EPS of $2.65, surpassing expectations. Net revenues hit $14.46 billion, reflecting a 4...

cantor-fitzgerald-reiterates-overweight-on-abbvie-maintains-200-price-target
Cantor Fitzgerald Reiterates Overweight on...
07/26/2024 17:24:11

Cantor Fitzgerald analyst Louise Chen reiterates AbbVie (NYSE:ABBV) with a Overweight and maintains $200 price target.

lockheed-martin-to-rally-over-14-here-are-10-top-analyst-forecasts-for-friday
Lockheed Martin To Rally Over 14%? Here Ar...
07/26/2024 14:27:18

truist-securities-reiterates-buy-on-abbvie-raises-price-target-to-210
Truist Securities Reiterates Buy on AbbVie...
07/26/2024 12:48:11

Truist Securities analyst Robyn Karnauskas reiterates AbbVie (NYSE:ABBV) with a Buy and raises the price target from $195 to...

wells-fargo-maintains-overweight-on-abbvie-raises-price-target-to-205
Wells Fargo Maintains Overweight on AbbVie...
07/26/2024 12:43:10

Wells Fargo analyst Mohit Bansal maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $200 to $205.

barclays-maintains-overweight-on-abbvie-raises-price-target-to-200
Barclays Maintains Overweight on AbbVie, R...
07/26/2024 11:39:04

Barclays analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $187 to $200.

abbvie-gains-eu-approval-for-skyrizi-to-treat-moderately-to-severely-active-ulcerative-colitis-in-adults
AbbVie Gains EU Approval For SKYRIZI To Tr...
07/26/2024 06:48:21

The marketing authorization for SKYRIZI® (risankizumab) marks its fourth approved indication in the European Union The appro...

stocks-rebound-as-us-economy-flexes-muscles-small-caps-rally-gold-falls-whats-driving-markets-thursday
Stocks Rebound As US Economy Flexes Muscle...
07/25/2024 17:00:09

Wall Street strongly rebounded Thursday after Wednesday’s slump, driven by stronger-than-expected economic growth in the last q...

abbvies-q2-earnings-beat-estimates-raises-annual-profit-on-strong-sales-from-newer-immunology-and-cancer-drugs
AbbVie's Q2 Earnings Beat Estimates, Raise...
07/25/2024 14:18:07

AbbVie Inc. reported Q2 adjusted EPS of $2.65, beating the $2.57 consensus, with net revenues at $14.46 billion. Immunology sal...

abbvie-exec-announces-discontinuation-of-further-development-of-experimental-alzheimers-drug-abbv-916-as-standalone-antibody
AbbVie Exec Announces Discontinuation Of F...
07/25/2024 13:37:54

- Conference Call

abbvie-raises-2024-adjusted-diluted-eps-guidance-from-1061-1081-to-1071-1091-versus-consensus-of-1078-which-includes-an-unfavorable-impact-of-060-per-share-related-to-acquired-iprd-and-milestones-expense-incurred-year-to-date-through-q2-2024
AbbVie Raises 2024 Adjusted Diluted EPS Gu...
07/25/2024 11:39:21

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION